Summit Investment Advisors »

Acelyrin shares owned by Summit Investment Advisors

Quarter-by-quarter ownership of Acelyrin (SLRN) shares owned by Summit Investment Advisors from 13F filings

Historical chart of Summit Investment Advisors investment in Acelyrin

Tip: Access up to 7 years of quarterly data

All positions including Acelyrin held by Summit Investment Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acelyrin by Summit Investment Advisors

Quarter filed Position value Share count Share price at filing
2023-12-31 $25k 3.3k 7.46
2023-09-30 $34k 3.3k 10.17

More positions owned by Summit Investment Advisors

Apple (AAPL)
Microsoft Corporation (MSFT)
Vanguard Europe Pacific ETF (VEA)
Ishares Tr Etf (IVV)
Amazon (AMZN)
Vanguard S&p 500 Etf idx (VOO)
iShares Lehman Aggregate Bond (AGG)
NVIDIA Corporation (NVDA)
Alphabet Inc Class C cs (GOOG)
Spdr Ser Tr Etf (ONEV)
iShares S&P 500 Growth Index (IVW)
Broadcom (AVGO)
Vanguard Total Bond Market ETF (BND)
iShares S&P 500 Value Index (IVE)
Facebook Inc cl a (META)

View all positions for Summit Investment Advisors

Top funds holding Acelyrin

Citadel Advisors
Vanguard Group
BlackRock
Opaleye Management
OrbiMed Advisors
venBio Partners
Artal Group
Jpmorgan Chase & Co
Samsara BioCapital
Ikarian Capital
Blue Owl Capital Holdings
Henderson Group
Decheng Capital
Logos Global Management
Kynam Capital Management

View all funds holding Acelyrin